Tumor presence induces global immune changes and enhances nanoparticle clearance

ACS Nano

Volumn 10, Issue 1, 2016, Pages 861-870

  Kai, Marc P ^a   Brighton, Hailey E ^b,c   Fromen, Catherine A ^a   Shen, Tammy W ^b   Luft, J Christopher ^b   Luft, Yancey E ^d   Keeler, Amanda W ^b   Robbins, Gregory R ^b   Ting, Jenny P Y ^b   Zamboni, William C ^b   Bear, James E ^b,c,d   DeSimone, Joseph M ^a,b,c  

^a North Carolina State University   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d The University of North Carolina at Chapel Hill   (United States)

Author keywords

Immunology; Intravital; Nanoparticle; Orthotopic; Pharmacokinetic

Indexed keywords

IMMUNE SYSTEM; IMMUNOLOGY; PHARMACOKINETICS; TUMORS;

HYDROGEL NANOPARTICLES; IMMUNE FUNCTION; INTRAVITAL; LONG CIRCULATING; ORTHOTOPIC; THERAPEUTIC EFFICACY; TUMOR ACCUMULATION;

NANOPARTICLES;

ANTINEOPLASTIC AGENT; CISPLATIN; HYDROGEL; NANOPARTICLE;

ANATOMY AND HISTOLOGY; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; EAR; HUMAN; HYDROGEL; IMMUNOLOGY; INNATE IMMUNITY; LIVER; LUNG; LUNG NEOPLASMS; MACROPHAGE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PRIMARY CELL CULTURE; SPLEEN; TIME LAPSE IMAGING; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DRUG COMPOUNDING; EAR; HUMANS; HYDROGELS; IMMUNITY, INNATE; LIVER; LUNG; LUNG NEOPLASMS; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, NUDE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PRIMARY CELL CULTURE; SPLEEN; TIME-LAPSE IMAGING;

EID: 84990978818     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/acsnano.5b05999     Document Type: Article

References (52)

1. Wang, A. Z.; Langer, R.; Farokhzad, O. C. Nanoparticle Delivery of Cancer Drugs. Annu. Rev. Med. 2012, 63, 185-198.
2. Fidler, I. J. Rationale and Methods For the Use of Nude Mice to Study the Biology and Therapy of Human Cancer Metastasis. Cancer Metastasis Rev. 1986, 5, 29-49.
3. Marusyk, A.; Almendro, V.; Polyak, K. Intra-Tumour Heterogeneity: A Looking Glass For Cancer? Nat. Rev. Cancer 2012, 12, 323-334.
4. Balkwill, F. R.; Capasso, M.; Hagemann, T. The Tumor Microenvironment at a Glance. J. Cell Sci. 2012, 125, 5591-5596.
5. Whiteside, T. L. The Tumor Microenvironment and Its Role in Promoting Tumor Growth. Oncogene 2008, 27, 5904-5912.
6. Combest, A. J.; Roberts, P. J.; Dillon, P. M.; Sandison, K.; Hanna, S. K.; Ross, C.; Habibi, S.; Zamboni, B.; Muller, M.; Brunner, M.; et al. Genetically Engineered Cancer Models, But Not Xenografts, Faithfully Predict Anticancer Drug Exposure in Melanoma Tumors. Oncologist 2012, 17, 1303-1316.
7. Richmond, A.; Su, Y. Mouse Xenograft Models vs GEM Models For Human Cancer Therapeutics. Dis. Models & Mech. 2008, 1, 78-82.
8. Nel, A. E.; Madler, L.; Velegol, D.; Xia, T.; Hoek, E. M. V.; Somasundaran, P.; Klaessig, F.; Castranova, V.; Thompson, M. Understanding Biophysicochemical Interactions at the Nano-Bio Interface. Nat. Mater. 2009, 8, 543-557.
9. Albanese, A.; Tang, P. S.; Chan, W. C. W. The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems. Annu. Rev. Biomed. Eng. 2012, 14, 1-16.
10. Owens, D. E., III; Peppas, N. A. Opsonization, Biodistribution, and Pharmacokinetics of Polymeric Nanoparticles. Int. J. Pharm. 2006, 307, 93-102.
11. Sun, X.; Rossin, R.; Turner, J. L.; Becker, M. L.; Joralemon, M. J.; Welch, M. J.; Wooley, K. L. An Assessment of the Effects of Shell Cross-Linked Nanoparticle Size, Core Composition, and Surface PEGylation on In Vivo Biodistribution. Biomacromolecules 2005, 6, 2541-2554.
12. Kiessling, R.; Wasserman, K.; Horiguchi, S.; Kono, K.; Sjoberg, J.; Pisa, P.; Petersson, M. Tumor-Induced Immune Dysfunction. Cancer Immunol. Immunother. 1999, 48, 353-362.
13. Shurin, M. R.; Lu, L.; Kalinski, P.; Stewart-Akers, A. M.; Lotze, M. T. Th1/Th2 Balance in Cancer, Transplantation and Pregnancy. Springer Semin. Immunopathol. 1999, 21 , 339-359.
14. Bronte, V.; Serafini, P.; Apolloni, E.; Zanovello, P. Tumor-Induced Immune Dysfunctions Caused by Myeloid Suppressor Cells. J. Immunother. 2001 , 24, 431-446.
15. Kusmartsev, S.; Gabrilovich, D. I. Immature Myeloid Cells and Cancer-Associated Immune Suppression. Cancer Immunol. Immun-other. 2002, 51, 293-298.
16. Serafini, P.; De Santo, C.; Marigo, I.; Cingarlini, S.; Dolcetti, L.; Gallina, G.; Zanovello, P.; Bronte, V. Derangement of Immune Responses by Myeloid Suppressor Cells. Cancer Immunol. Immunother. 2004, 53, 64-72.
17. Sica, A.; Bronte, V. Altered Macrophage Differentiation and Immune Dysfunction in Tumor Development. J. Clin. Invest. 2007, 117, 1155-1166.
18. Jones, S. W.; Roberts, R. A.; Robbins, G. R.; Perry, J. L.; Kai, M. P.; Chen, K.; Bo, T.; Napier, M. E.; Ting, J. P. Y.; DeSimone, J. M.; et al. Nanoparticle Clearance is Governed by Th1/Th2 Immunity and Strain Background. J. Clin. Invest. 2013, 123, 3061-3073.
19. Euliss, L. E.; DuPont, J. A.; Gratton, S.; DeSimone, J. Imparting Size, Shape, and Composition Control of Materials for Nanomedicine. Chem. Soc. Rev. 2006, 35, 1095-1104.
20. Rolland, J. P.; Maynor, B. W.; Euliss, L. E.; Exner, A. E.; Denison, G. M.; DeSimone, J. M. Direct Fabrication and Harvesting of Monodisperse, Shape-Specific Nanobiomaterials. J. Am. Chem. Soc. 2005, 127, 10096-10100.
21. Kersey, F. R.; Merkel, T. J.; Perry, J. L.; Napier, M. E.; Desimone, J. M. Effect of Aspect Ratio and Deformability on Nanoparticle Extravasation Through Nanopores. Langmuir 2012, 28, 8773-8781.
22. Perry, J. L.; Reuter, K. G.; Kai, M. P.; Herlihy, K. P.; Jones, S. W.; Luft, J. C.; Napier, M.; Bear, J. E.; DeSimone, J. M. PEGylated PRINT Nanoparticles: The Impact of PEG Density on Protein Binding, Macrophage Association, Biodistribution, and Pharmacoki-netics. Nano Lett. 2012, 12, 5304-5310.
23. Merkel, T. J.; Jones, S. W.; Herlihy, K. P.; Kersey, F. R.; Shields, A. R.; Napier, M.; Luft, J. C.; Wu, H.; Zamboni, W. C.; Wang, A. Z.; et al. Using Mechanobiological Mimicry of Red Blood Cells to Extend Circulation Times of Hydrogel Microparticles. Proc. Natl. Acad. Sci. U. S. A. 2011 , 108, 586-591.
24. Hughes, E. L.; Gavins, F. N. E. Troubleshooting methods: Using Intravital Microscopy in Drug Research. J. Pharmacol. Toxicol. Methods 2010, 61 , 102-112.
25. Hu, W.; Pasare, C. Location, Location, Location: Tissue-Specific Regulation of Immune Responses. J. Leukocyte Biol. 2013, 94, 409-421.
26. Morrison, J. G.; White, P.; McDougall, S.; Firth, J. W.; Woolfrey, S. G.; Graham, M. A.; Greenslade, D. Validation of a Highly Sensitive ICP-MS Method for the Determination of Platinum in Biofluids: Application to Clinical Pharmacokinetic Studies With Oxaliplatin. J. Pharm. Biomed. Anal. 2000, 24, 1-10.
27. Kai, M. P.; Keeler, A. W.; Perry, J. L.; Reuter, K. G.; Luft, J. C.; O'Neal, S. K.; Zamboni, W. C.; DeSimone, J. M. Evaluation of Drug Loading, Pharmacokinetic Behavior, and Toxicity of a Cisplatin-Containing Hydrogel Nanoparticle. J. Controlled Release 2015, 204, 70-7.
28. Kwon, M.; Berns, A. Mouse Models for Lung Cancer. Mol. Oncol. 2013, 7, 165-177.
29. Mantovani, A.; Locati, M. Tumor-Associated Macrophages as a Paradigm of Macrophage Plasticity, Diversity, and Polarization: Lessons and Open Questions. Arterioscler., Thromb., Vasc. Biol. 2013, 33, 1478-1483.
30. Mantovani, A.; Sozzani, S.; Locati, M.; Allavena, P.; Sica, A. Macrophage Polarization: Tumor-Associated Macrophages as a Paradigm for Polarized M2Mononuclear Phagocytes. Trends Immunol. 2002, 23, 549-555.
31. Gabrilovich, D. I.; Ostrand-Rosenberg, S.; Bronte, V. Coordinated Regulation of Myeloid Cells by Tumours. Nat. Rev. Immunol. 2012, 12, 253-268.
32. Jenne, C. N.; Kubes, P. Immune Surveillance by the Liver. Nat. Immunol. 2013, 14, 996-1006.
33. Sheth, K.; Bankey, P. The Liver as an Immune Organ. Curr. Opin Crit Care 2001, 7, 99-104.
34. Finn, O. J. Cancer Immunology. N. Engl. J. Med. 2008, 358, 2704-2715.
35. Van Ginderachter, J.; Meerschaut, S.; Liu, Y.; Brys, L.; De Groeve, K.; Hassanzadeh Ghassabeh, G.; Raes, G.; De Baetselier, P. Peroxisome Proliferator-Activated Receptor Gamma (PPARgamma) Ligands Reverse CTL Suppression by Alternatively Activated (M2) Macrophages in Cancer. Blood 2006, 108, 525-535.
36. Biswas, S. K.; Mantovani, A. Macrophage Plasticity and Interaction With Lymphocyte Subsets: Cancer as a Paradigm. Nat. Immunol. 2010, 11, 889-896.
37. Caron, W. P.; Lay, J. C.; Fong, A. M.; La-Beck, N. M.; Kumar, P.; Newman, S. E.; Zhou, H.; Monaco, J. H.; Clarke-Pearson, D. L.; Brewster, W. R.; et al. Translational Studies of Phenotypic Probes for the Mononuclear Phagocyte System and Liposomal Pharmacology. J. Pharmacol. Exp. Ther. 2013, 347, 599-606.
38. Song, G.; Tarrant, T. K.; White, T. F.; Barrow, D. A.; Santos, C. M.; Timoshchenko, R. G.; Hanna, S. K.; Ramanathan, R. K.; Lee, C. R.; Bae-Jump, V. L.; et al. Roles of Chemokines CCL2 and CCL5 in the Pharmacokinetics ofPEGylated Liposomal Doxorubicin in vivo and in Patients With Recurrent Epithelial Ovarian Cancer. Nanomedicine 2015, 11 , 1797-1807.
39. Yuan, Z.; Mehta, H. J.; Mohammed, K.; Nasreen, N.; Roman, R.; Brantly, M.; Sadikot, R. T. TREM-1 is Induced in Tumor Associated Macrophages by Cyclo-oxygenase Pathway in Human Non-Small Cell Lung Cancer. PLoS One 2014, 9, e94241.
40. Cho, H. J.; Jung, J. I.; Lim, D. Y.; Kwon, G. T.; Her, S.; Park, J. H.; Park, J. H. Bone Marrow-Derived, Alternatively Activated Macrophages Enhance Solid Tumor Growth and Lung Metastasis of Mammary Carcinoma Cells in a Balb/C Mouse Orthotopic Model. Breast Cancer Res. 2012, 14, R81.
41. Han, W.; Joo, M.; Everhart, M. B.; Christman, J. W.; Yull, F. E.; Blackwell, T. S. Myeloid Cells Control Termination of Lung Inflammation Through the NF-kappaB Pathway. Am. J. Physiol Lung Cell Mol. Physiol 2009, 296, L320-327.
42. Muller-Quernheim, U. C.; Potthast, L.; Muller-Quernheim, J.; Zissel, G. Tumor-Cell Co-Culture Induced Alternative Activation of Macrophages is Modulated by Interferons In Vitro. J. Interferon Cytokine Res. 2012, 32, 169-177.
43. Petkova, S. B.; Yuan, R.; Tsaih, S.; Schott, W.; Roopenian, D. C.; Paigen, B. Genetic Influence on Immune Phenotype Revealed Strain-Specific Variations in Peripheral Blood Lineages. Physiol. Genomics 2008, 34, 304-314.
44. Burkholder, B.; Huang, R.-Y.; Burgess, R.; Luo, S.; Jones, V. S.; Zhange, W.; Lv, Z.-Q.; Gao, C.-Y.; Wang, B.-L.; Zhang, Y.-M.; et al. Tumor-Induced Perturbations of Cytokines and Immune Cell Networks. Biochim. Biophys. Acta, Rev. Cancer 2014, 1845, 182-201.
45. Guzman, J.; Iglesias, M. T.; Riande, E.; Compan, V.; Andrio, A. Synthesis and Polymerization of Acrylic Monomers With Hydrophilic Long Side Groups. Oxygen Transport Through Water Swollen Membranes Prepared From These Polymers. Polymer 1997, 38, 5227-5232.
46. Peng, L.; Feng, L.; Yuan, H.; Benhabbour, S. R.; Mumper, R. J. Development of a Novel Orthotopic Non-Small Cell Lung Cancer Model and Therapeutic Benefit of 2′-(2-Bromohexadecanoyl)-Docetaxel Conjugate Nanoparticles. Nanomedicine 2014, 10, 14971506.
47. Rozenberg, G. I.; Monahan, K. B.; Torrice, C.; Bear, J. E.; Sharpless, N. E. Metastasis in an Orthotopic Murine Model of Melanoma is Independent of RAS/RAF Mutation. Melanoma Res. 2010, 20, 361-371.
48. Weischenfeldt, J.; Porse, B. Bone Marrow-Derived Macrophages (BMM): Isolation and Applications. Cold SpringHarb. Protoc. 2008, 3, 1-6.
49. Tong, L.; He, W.; Zhang, Y.; Zheng, W.; Cheng, J.-X. Visualizing Systemic Clearance and Cellular Level Biodistribution of Gold Nanorods by Intrinsic Two-Photon Luminescence. Langmuir 2009, 25, 12454-12459.
50. Zhang, Y.; Huo, M.; Zhou, J.; Xie, S. PKSolver: An Add-in Program for Pharmacokinetic and Pharmacodynamic Data Analysis in Microsoft Excel. Comput. Methods Programs Biomed 2010, 99, 306314.
51. Akaike, H. A New Look at the Statistical Model Identification. IEEE Trans. Autom. Control 1974, 19, 716-723.
52. Herzenberg, L.; Tung, J.; Moore, W.; Herzenberg, L.; Parks, D. R. Interpreting Flow Cytometry Data: A Guide for the Perplexed. Nat. Immunol. 2006, 7, 681-685.